Analysts at Leerink Swann maintain their "outperform" rating on Pharmasset Inc (NASDAQ: VRUS). The target price for VRUS is set to $27.
VRUS has announced that the interim analysis of Phase IIb trial of nucleoside HCV polymerase inhibitor RG7128 by the data monitoring committee (DMC) was positive. According to Leerink Swann, renal toxicity signals seen in animal studies do not seem to be a matter of concern.
RG7128 is emerging as an outstanding agent in the potentially vital class of nucleoside HCV polymerase inhibitors, Leerink Swann says. The effect of the discontinuation of high-dose of ITMN-191 on the INFORM program has to be determined still, Leerink Swann adds.
